Otamixaban

Otamixaban

Clinical data
ATC code	none
Identifiers
IUPAC name Methyl (2R,3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate
CAS Number	193153-04-7  N
PubChem CID	5496659
ChemSpider	4593439  Y
UNII	S173RED00L
ChEMBL	ChEMBL46618  Y
CompTox Dashboard (EPA)	DTXSID40172917
Chemical and physical data
Formula	C25H26N4O4
Molar mass	446.507 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(OC)[C@H](Cc1cc(C(=[N@H])N)ccc1)[C@H](NC(=O)c3ccc(c2cc[n+]([O-])cc2)cc3)C
InChI InChI=1S/C25H26N4O4/c1-16(22(25(31)33-2)15-17-4-3-5-21(14-17)23(26)27)28-24(30)20-8-6-18(7-9-20)19-10-12-29(32)13-11-19/h3-14,16,22H,15H2,1-2H3,(H3,26,27)(H,28,30)/t16-,22-/m1/s1 Y Key:PFGVNLZDWRZPJW-OPAMFIHVSA-N Y
NY  (what is this?)    (verify)

Otamixaban (INN) is an experimental injectable anticoagulant direct factor Xa inhibitor ^[1] that was investigated for the treatment for acute coronary syndrome. In 2013, Sanofi announced that it had ended development of the drug candidate after poor performance in a Phase III clinical trial. ^{[2] [3]}

References

1. Guertin KR, Choi YM (2007). "The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development" . Curr. Med. Chem. 14 (23): 2471–81. doi:10.2174/092986707782023659. PMID   17979700.
2. "AstraZeneca, Sanofi Cut Programs". Chemical & Engineering News. 91 (23). American Chemical Society: 17. June 10, 2013. Sanofi is ending development on two compounds, the anticancer compound iniparib and the anticoagulant otamixaban, both of which flunked Phase III studies.
3. "Sanofi's Investigational Iniparib, Otamixaban Fail To Meet Goals, Ends Programs". RTT news. Retrieved 11 April 2014.